Showing results (151-160 of 1,348) with videos related to

Sort By:
Pageof 135
Clinical Pharmacology in Drug Development|July 21, 2021
A Bioequivalence Study of Avanafil in Healthy Chinese Male Subjects Under Fasting and Fed Conditions: Results of a Randomized, Open-Label, Single-Dose, 2-Sequence, 2-Period Crossover StudyXiuhua Ren, Hengyi Yu, Xingxing Qi, et al.
Clinical Pharmacology in Drug Development|June 17, 2021
Pharmacokinetics of Meloxicam Tablets in Healthy Chinese Adults in the Fasting and Fed States: A Single-Site, Single-Dose, Randomized, Open, 2-Period, 2-Sequence, Crossover Bioequivalence StudyJin Yu, Yannan Wang, Yi Wu, et al.
Clinical Pharmacology in Drug Development|June 8, 2021
Intravaginal Tolterodine Formulation Intended for Overactive Bladder Treatment-Results of a Pharmacokinetic Phase I Pilot Study in Healthy, Postmenopausal WomenFrank Donath, Larissa Hoffmann, Marina Todorova-Sanjari, et al.
Clinical Pharmacology in Drug Development|June 12, 2021
Single-Dose Pharmacokinetics and Tolerability of the Oral Epidermal Growth Factor Receptor Inhibitor Mobocertinib (TAK-788) in Healthy Volunteers: Low-Fat Meal Effect and Relative Bioavailability of 2 Capsule ProductsSteven Zhang, Shu Jin, Celina Griffin, et al.
Clinical Pharmacology in Drug Development|June 12, 2021
First-in-Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of Pirepemat, a Cortical Enhancer, in Healthy VolunteersErik Rein-Hedin, Folke Sjöberg, Susanna Waters, et al.
Clinical Pharmacology in Drug Development|April 8, 2020
First-in-Human Studies of MW01-6-189WH, a Brain-Penetrant, Antineuroinflammatory Small-Molecule Drug Candidate: Phase 1 Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Studies in Healthy Adult VolunteersLinda J Van Eldik, Lumy Sawaki, Karen Bowen, et al.
Clinical Pharmacology in Drug Development|March 21, 2020
Levocetirizine Oral Disintegrating Tablet: A Randomized Open-Label Crossover Bioequivalence Study in Healthy Japanese VolunteersHiroko Ino, Masanari Shiramoto, Takashi Eto, et al.
Clinical Pharmacology in Drug Development|April 3, 2020
The Effect of CYP3A Induction and Inhibition on the Pharmacokinetics of Laquinimod, a Novel NeuroimmunomodulatorAnna Elgart, David J Greenblatt, Pippa S Loupe, et al.
Clinical Pharmacology in Drug Development|December 17, 2020
Assessment of Vedolizumab Disease-Drug-Drug Interaction Potential in Patients With Inflammatory Bowel DiseasesWan Sun, Richard A Lirio, Jennifer Schneider, et al.
Clinical Pharmacology in Drug Development|December 30, 2020
Phase 1 Study of the Effects of the Tuberculosis Treatment Pretomanid, Alone and in Combination With Moxifloxacin, on the QTc Interval in Healthy VolunteersMengchun Li, George A Saviolakis, Wael El-Amin, et al.
Pageof 135